| Recruiting | The Efficacy of Vosevi in Treating DAA-experienced Patients NCT06180590 | The Third Affiliated Hospital of Guangzhou Medical University | — |
| Withdrawn | Study of AT-777 in Healthy Subjects and AT-777 in Combination With AT-527 in HCV-Infected Subjects NCT04309734 | Atea Pharmaceuticals, Inc. | Phase 1 / Phase 2 |
| Unknown | The Efficacy and Safety of 12-week SOF/VEL Regimen Combined With Prophylactic Use of TAF for Treatment-naïve G NCT04997564 | Peking University First Hospital | Phase 4 |
| Completed | Combined Ribavirin With Sofosbuvir/Velpatasvir/Voxilaprevir in Retreatment of Chronic Hepatitis C Non-responde NCT04695769 | Helwan University | Phase 4 |
| Withdrawn | Single Patient Protocol for Donor HCV-positive to Recipient HCV-negative Kidney Transplant in a Patient at Ris NCT04614142 | Massachusetts General Hospital | Phase 4 |
| Completed | Drug-drug Interaction Study Between HEC74647PA Capsule and HEC110114 Tablets in Healthy Subjects NCT04232514 | Sunshine Lake Pharma Co., Ltd. | Phase 1 |
| Unknown | Cross Sectional Survey on the Burden, Impacts and Causes of Hepatitis C Virus (HCV) Outbreak in South West Reg NCT04136405 | ANRS, Emerging Infectious Diseases | — |
| Completed | The Tolerability, Pharmacokinetics and Pharmacodynamics Study of HEC110114 Tablets in HCV-infected Subjects NCT04202952 | Sunshine Lake Pharma Co., Ltd. | Phase 1 / Phase 2 |
| Completed | Study of Telemedicine Stress Management and Lifestyle Group Intervention for HCV Patients NCT04198584 | University of North Carolina, Chapel Hill | N/A |
| Completed | The Tolerability, Pharmacokinetics and Pharmacodynamics Study of HEC74647 in HCV-infected Subjects NCT04201275 | Sunshine Lake Pharma Co., Ltd. | Phase 1 |
| Completed | Evaluation of the Efficacy and Safety of the Fixed-dose Combination Sofosdac® 400mg/60mg in Patients With Chro NCT05138523 | Beker Laboratories | — |
| Unknown | Metabolic Changes in Chronic HCV Patients Receiving DAAS NCT04211844 | Ain Shams University | — |
| Active Not Recruiting | Enhancing Access to Care for Chronic Hepatitis C Infected Populations in Hong Kong NCT03993925 | The University of Hong Kong | — |
| Unknown | Assessment Effects After Direct Acting Antiviral in Chronic Hepatitis c Virus Patients NCT03163849 | Assiut University | Phase 3 |
| Unknown | An Observational Cohort Study of Clinical Outcomes After Antiviral Treatment of Chronic Hepatitis C NCT04301882 | Beijing Ditan Hospital | — |
| Unknown | Monitoring of Hepatitis C Treatment Using Telemedicine - a Clinical Trial in Public Health System in Brazil NCT04039698 | Hospital de Clinicas de Porto Alegre | N/A |
| Unknown | Frequency of Anxiety and Depression in Chronic Hepatitis C Patients Recieving Direct-Acting Antiviral Agents NCT03894696 | Assiut University | — |
| Unknown | Observational Cohort Study of Clinical Outcomes After Antiviral Therapy for Chronic Hepatitis C NCT04071353 | Beijing Ditan Hospital | — |
| Unknown | Glecaprevir/Pibrentasvir Real-world Study in China NCT03941821 | Tongji Hospital | — |
| Completed | Study of AT-527 in Combination With Daclatasvir in Subjects With Hepatitis C Virus (HCV) Infection NCT04019717 | Atea Pharmaceuticals, Inc. | Phase 2 |
| Completed | Changes in Liver Fibrosis, Lipid Profile and Insulin Resistance in HCV Patients Who Received Antiviral Therapy NCT03612973 | Assiut University | N/A |
| Unknown | Real-world Effectiveness and Safety of Treatment With DAAs in Patients With CHC(Chronic Hepatitis C) NCT03887637 | Third Affiliated Hospital, Sun Yat-Sen University | — |
| Completed | The Tolerability and Pharmacokinetics Study of HEC110114 Tablets in Healthy Adult Subjects NCT03903081 | Sunshine Lake Pharma Co., Ltd. | Phase 1 |
| Terminated | Grazoprevir/Elbasvir for Genotype 1b Chronic Hepatitis C After Liver or Kidney Transplantation NCT03723824 | Taichung Veterans General Hospital | Phase 4 |
| Unknown | The Effect Of DAAs on miRNA-122 And Insulin Resistance In Chronic HCV Patients NCT03687229 | Assiut University | — |
| Completed | Study to Determine the Hepatitis C Virus Infection Prevalence Among Patients Attended Primarily for Vasculitis NCT03693586 | Hospital General de Mexico | — |
| Unknown | Hepatitis C Elimination in the Netherlands NCT04208035 | Radboud University Medical Center | — |
| Completed | The Tolerability and Pharmacokinetics Study of HEC74647PA Capsule in Healthy Adult Subjects NCT03673696 | Sunshine Lake Pharma Co., Ltd. | Phase 1 |
| Completed | Study of CDI-31244 in Combination With Sofosbuvir (SOF) and Velpatasvir (VEL) NCT03501550 | Cocrystal Pharma, Inc. | Phase 2 |
| Unknown | Long Term Follow up of Chronic HCV Patients Receiving DAAS NCT05170490 | Sohag University | — |
| Terminated | Study of Daclatasvir-based Therapy in Chinese Participants With Chronic Hepatitis C (CHC) NCT03500562 | Bristol-Myers Squibb | — |
| Terminated | Ezetimibe as a Safe and Efficacious Treatment for Chronic Hepatitis C NCT02971033 | VA Office of Research and Development | Phase 2 |
| Unknown | Sysmex-XN 20 Analyser to Assess Lymphocyte Subsets and Other Haematological Parameters in Chronic/Acute Viral NCT03495570 | University College, London | — |
| Unknown | Treatment of HCV-Infected Recent Injection Drug Users in U.S. Liver Clinics NCT05895448 | Center For Hepatitis C, Atlanta, GA | Phase 4 |
| Completed | Hematologic Profile, Vit. B12 and Folic Acid in Cirrhotics Received Sofosbuvir and Daclatasvir With or Without NCT03283176 | Assiut University | — |
| Terminated | Re-treatment of HCV Following DAA Failure NCT03483987 | Sanjay Gandhi Postgraduate Institute of Medical Sciences | N/A |
| Unknown | "Real Life" Evaluation of Efficacy and Safety of Direct Antiviral Agents (DAAs) for the Treatment of Hepatitis NCT03510637 | ANRS, Emerging Infectious Diseases | — |
| Completed | A Study to Evaluate the Pharmacokinetics and Safety of ASC16 Tablets in Healthy Volunteers in China NCT03430830 | Ascletis Pharmaceuticals Co., Ltd. | Phase 1 |
| Completed | The Tolerability and Pharmacokinetics Study of Kangdaprevir Sodium Tablet in Healthy Adult Subjects NCT03811678 | Sunshine Lake Pharma Co., Ltd. | Phase 1 |
| Unknown | A Trial to Evaluate Safety, Tolerability, PK and Antiviral Activity of MB-110 in Hepatitis C Virus Infected Pa NCT02617615 | Microbio Co Ltd | Phase 1 |
| Completed | Statins in Chronic Hepatitis C Patients Receiving Sofosbuvir/Daclatasvir Combination NCT03490097 | Ain Shams University | Phase 2 / Phase 3 |
| Completed | Efficacy and Tolerability of Grazoprevir and Elbasvir in Patients With Chronic Genotype 1 HCV and HIV Co-infec NCT03098121 | Taoyuan General Hospital | Phase 4 |
| Completed | 'Fibrosis in the Lost Hepatitis C Population - Track, Trace and Treat' NCT03088917 | Radboud University Medical Center | — |
| Completed | Role of the Host Immunity in the Non-response to Direct Anti-viral Agent (DAA) Therapy NCT03155113 | Azienda Ospedaliero-Universitaria di Parma | N/A |
| Completed | Study of AT-527 in Healthy and HCV-Infected Subjects NCT03219957 | Atea Pharmaceuticals, Inc. | Phase 1 |
| Completed | Pulmonary Arterial Hypertension in Patients With Direct-Acting Antiviral Medications for Hepatitis C Virus Inf NCT04094272 | Kantonsspital Olten | — |
| Completed | Sofosbuvir/Velpatasvir in Adults With Chronic Hepatitis C Virus Infection Who Are on Dialysis for End Stage Re NCT03036852 | Gilead Sciences | Phase 2 |
| Completed | Real World Evidence of the Effectiveness of Paritaprevir/Ritonavir (r) - Ombitasvir, + Dasabuvir Without Ribav NCT03053180 | AbbVie | — |
| Completed | Real World Evidence of the Effectiveness of Paritaprevir/r - Ombitasvir, ± Dasabuvir, ± Ribavirin in Patients NCT02851069 | AbbVie | — |
| Completed | Viekira Pak or Mavyret Treatment for Patient With Chronic Kidney Disease and Hepatitis C NCT02946034 | Massachusetts General Hospital | Phase 4 |
| Unknown | Safety and Effect of Elbasvir/Grazoprevir Combination Therapy in Hemodialysis Patients With Chronic Hepatitis NCT03022006 | Norte Study Group | Phase 4 |
| Unknown | Eliminate Hepatitis C/EC Partnership Evaluation Protocol NCT04061551 | Macfarlane Burnet Institute for Medical Research and Public Health Ltd | N/A |
| Terminated | Pilot Study Of The Effect Of Rifaximin On B-Cell Dysregulation In Cirrhosis NCT01951209 | David E. Kaplan, MD MSc | N/A |
| Unknown | Efficacy and Safety of Qurevo Plus Ribavirin Based Therapy for Hepatitis C With or Without Cirrhosis in Haemod NCT03067883 | Ain Shams University | Phase 2 |
| Completed | Simplifying Hepatitis C Antiviral Therapy in Rwanda for Elsewhere in the Developing World NCT02964091 | Partners in Health | Phase 4 |
| Unknown | Regression of Liver Fibrosis After Daclatasvir and Asunaprevir Treatment NCT02865369 | Sang Gyune Kim | — |
| Completed | Effectiveness of Paritaprevir/Ritonavir, Ombitasvir, + Dasabuvir, ± Ribavirin in Patients With Chronic Hepatit NCT02807402 | AbbVie | — |
| Completed | Real World Evidence of the Effectiveness of Paritaprevir/r - Ombitasvir, ± Dasabuvir, ± Ribavirin and Patient NCT02803138 | AbbVie | — |
| Unknown | Management of Patients With Hepatitis C in a Public Health Care Setting: The Punjab Model NCT03488485 | Post Graduate Institute of Medical Education and Research, Chandigarh | N/A |
| Unknown | DAA Therapy in Pediatric Patients With Chronic Hepatitis C NCT03481036 | Post Graduate Institute of Medical Education and Research, Chandigarh | N/A |
| Completed | Efficacy and Safety of Danoprevir/r + PR 12week Triple Therapy in Treatment Naive Non-Cirrhotic G1 CHC China I NCT03020082 | Ascletis Pharmaceuticals Co., Ltd. | Phase 3 |
| Completed | Study of Oral Treatments for Hepatitis C NCT02786537 | University of Florida | Phase 4 |
| Completed | Effectiveness of Paritaprevir/r - Ombitasvir, ± Dasabuvir, ± Ribavirin in Patients With Chronic Hepatitis C - NCT02798315 | AbbVie | — |
| Completed | A Study to Evaluate the Efficacy and Safety of Experimental Drugs ABT- 493/ABT-530 in Adults With Chronic Hepa NCT02738138 | AbbVie | Phase 3 |
| Completed | Side Effects After Direct-acting Antiviral Treatment NCT03346941 | Hospices Civils de Lyon | — |
| Completed | A Study of Faldaprevir, TD-6450 and Other Antivirals in Participants With Genotype 1b Hepatitis C Virus Infect NCT02716428 | Trek Therapeutics, PBC | Phase 2 |
| Completed | Safety, Tolerability and Efficacy of Sofosbuvir, Velpatasvir, and Voxilaprevir in Subjects With Previous DAA E NCT02745535 | University of Maryland, Baltimore | Phase 2 |
| Completed | A Study to Evaluate the Safety and Efficacy of ABT-493/ABT-530 in Adult Post-Liver or Post-Renal Transplant Re NCT02692703 | AbbVie | Phase 3 |
| Completed | Observational, Multi-Center Study of the Real World Evidence of the Effectiveness of Paritaprevir/r - Ombitasv NCT02669940 | AbbVie | — |
| Completed | Real World Evidence of the Effectiveness of Paritaprevir/r - Ombitasvir, ± Dasabuvir, ± Ribavirin in Participa NCT02725866 | AbbVie | — |
| Completed | A Study to Investigate HCV Response Rates in Real World Patients: HEARTLAND Study NCT03710252 | American Research Corporation | Phase 4 |
| Unknown | Study to Investigate the Efficacy and Safety of Ledipasvir/Sofosbuvir Fixed-Dose Combination for 12 Weeks in S NCT02691728 | Peter J. Ruane, M.D., Inc. | Phase 4 |
| Completed | The Relationship Between MDSCs and NK Cells Activity of CHC Patient Treated by DAAs NCT03188276 | Third Affiliated Hospital, Sun Yat-Sen University | EARLY_Phase 1 |
| Completed | Real World Evidence of the Effectiveness of Paritaprevir/r - Ombitasvir, ± Dasabuvir, ± Ribavirin and Patient NCT02817594 | AbbVie | — |
| Completed | Efficacy and Safety of Danoprevir/r + PR 12-week Triple Therapy in Treatment-Naive, Non-Cirrhotic, G1 CHC Chin NCT03020004 | Ascletis Pharmaceuticals Co., Ltd. | Phase 2 |
| Completed | Long Term Follow-up of Hepatitis C Cured Patients NCT03246048 | Hospital Universitari Vall d'Hebron Research Institute | — |
| Completed | The Effectiveness of Paritaprevir/Ritonavir - Ombitasvir, ± Dasabuvir, ± Ribavirin in France NCT02618928 | AbbVie | — |
| Completed | A Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Adults With Chronic Hepatitis C Virus Genoty NCT02642432 | AbbVie | Phase 3 |
| Completed | Real World Evidence of the Effectiveness of Paritaprevir/r - Ombitasvir, ± Dasabuvir, ± Ribavirin in Patients NCT02615145 | AbbVie | — |
| Completed | A Study Comparing Efficacy and Safety of ABT-493/ABT-530 to Sofosbuvir Dosed With Daclatasvir in Adults With H NCT02640157 | AbbVie | Phase 3 |
| Completed | Pilot Treatment as Prevention for HCV Among Persons Who Actively Inject Drugs NCT02609893 | Phillip Coffin, MD, MIA | Phase 4 |
| Completed | Real World Evidence of the Effectiveness of Paritaprevir/r - Ombitasvir, ± Dasabuvir, ± Ribavirin in Patients NCT02636608 | AbbVie | — |
| Completed | Real World Evidence of the Effectiveness of Paritaprevir/Ritonavir, Ombitasvir, ± Dasabuvir, ± Ribavirin in Pa NCT02640547 | AbbVie | — |
| Completed | The Effectiveness of ABT-450/r - Ombitasvir, ± Dasabuvir, ± Ribavirin in Patients With Chronic Hepatitis C -An NCT02582671 | AbbVie | — |
| Completed | Impact on QoL and Cognitive Functioning of New Antiviral Therapies in Subjects With Chronic Hepatitis HCV-rela NCT03313154 | Azienda Ospedaliero Universitaria di Cagliari | — |
| Completed | A Study to Evaluate the Safety, Pharmacokinetics and Efficacy of the Combination of AL-335, Odalasvir, and Sim NCT02569710 | Alios Biopharma Inc. | Phase 2 |
| Completed | Effectiveness of Paritaprevir/r - Ombitasvir, ± Dasabuvir, ± Ribavirin in Patients With Chronic Hepatitis C in NCT02581189 | AbbVie | — |
| Completed | Paritaprevir/r - Ombitasvir, ± Dasabuvir, ± Ribavirin in Patients With Chronic Hepatitis C - An Observational NCT02582658 | AbbVie | — |
| Completed | A Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Subjects With Genotype 1 Infection NCT02604017 | AbbVie | Phase 3 |
| Completed | Anti-E1E2 (D32.10 Epitope-binding) Antibodies Status Prior Therapy Favors Direct-acting Antiviral Treatment Ef NCT03348059 | Hospices Civils de Lyon | — |
| Completed | A Study of Faldaprevir, Ribavirin and TD-6450 in Participants With Genotype 4 Hepatitis C Virus Infection NCT02593162 | Trek Therapeutics, PBC | Phase 2 |
| Unknown | Therapy With Ledipasvir/Sofosbuvir in Patients With Genotype 1 HCV Infection Receiving Opiate Substitution The NCT02638233 | Wilhelminenspital Vienna | Phase 4 |
| Unknown | Status of Chronic Liver Disease in Hepatitis C Virus (HCV) Patients Coinfected With Human Immunodeficiency Vir NCT02511496 | Maimónides Biomedical Research Institute of Córdoba | — |
| Completed | SR-BI and Antiviral Treatment Response in HCV NCT02714712 | Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation | — |
| Completed | Efficacy and Safety of Ravidasvir + Danoprevir/r 12-week Oral Therapy in Treatment-Naive Non Cirrhotic G1 CHC NCT03020095 | Ascletis Pharmaceuticals Co., Ltd. | Phase 2 |
| Completed | A Study to Evaluate the Effect of ACH-3102 and Simeprevir on AL-335 Pharmacokinetics in Healthy Volunteers NCT02512562 | Alios Biopharma Inc. | Phase 1 |
| Withdrawn | The Regression of Liver Fibrosis and Risk for Hepatocellular Carcinoma (ROLFH) Study NCT01831037 | University of Arkansas | — |
| Completed | Viral Kinetics, Interferon Stimulated Genes (ISGs) and mirRNA Among Subjects Infected With Different Hepatitis NCT02468648 | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Phase 2 |
| Withdrawn | The Effects of Adding TCM-700C on the Standard Combination Treatment for HCV Genotype 1 Patients(Phase III) NCT01890200 | TCM Biotech International Corp. | Phase 3 |
| Completed | Ombitasvir/ABT-450/Ritonavir and Dasabuvir Therapy With Low Dose Ribavirin (RBV), Full Dose RBV or RBV Add-On NCT02493855 | AbbVie | Phase 2 |
| Completed | Ombitasvir/ABT-450 (Paritaprevir)/Ritonavir With Dasabuvir and Ribavirin (RBV) in Treatment Naive and Treatmen NCT02476617 | AbbVie | Phase 3 |
| Completed | A Study to Evaluate the Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir With or Without NCT02442284 | AbbVie | Phase 3 |
| Completed | A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of ABT-493 and ABT-530 With and Without Ribavir NCT02446717 | AbbVie | Phase 2 / Phase 3 |
| Withdrawn | Hepatitis C Virus in Neutrophil Granulocyte Progenitor Cells NCT02545387 | Medical University of Graz | — |
| Unknown | A Study of the Efficacy and Safety of PPI-668 (NS5A Inhibitor) Plus Sofosbuvir, With or Without Ribavirin, in NCT02371408 | Pharco Pharmaceuticals | Phase 2 / Phase 3 |
| Completed | Transient Elastography to Assess Liver Fibrosis and Portal Hypertension in HCV Cirrhotic Patients Treated With NCT02439567 | Hospital Universitari Vall d'Hebron Research Institute | N/A |
| Completed | Efficacy and Safety Study of Simeprevir in Combination With Sofosbuvir in Subjects With Chronic Genotype 4 Hep NCT02250807 | Janssen R&D Ireland | Phase 3 |
| Completed | First in Human Study of AL-335; Single Dose, Food Effect in Healthy Volunteers; Multiple Doses in Chronic Hepa NCT02339207 | Alios Biopharma Inc. | Phase 1 |
| Completed | The Safety, Tolerability and Pharmacokinetic Study of Yimitasvir in Healthy Adults Subjects NCT03462173 | Sunshine Lake Pharma Co., Ltd. | Phase 1 |
| Completed | A Study to Evaluate the Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir With Ribavirin NCT02219477 | AbbVie | Phase 3 |
| Completed | Neutrophil Function During Therapy With Protease Inhibitors in Chronic Hepatitis C NCT02545335 | Medical University of Graz | — |
| Completed | Simeprevir in Combination With Sofosbuvir in Treatment-Naïve or -Experienced Adults With Chronic Genotype 4 He NCT02253550 | Peter J. Ruane, M.D. | Phase 2 |
| Completed | Asunaprevir/Daclatasvir Safety Surveillance in Japanese Patients With Chronic Hepatitis C NCT02250001 | Bristol-Myers Squibb | — |
| Completed | Ombitasvir/ABT-450/Ritonavir and Dasabuvir With or Without Ribavirin in HCV Genotype 1-Infected Adults With Ch NCT02207088 | AbbVie | Phase 3 |
| Completed | A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Co-Administration of ABT-493 and ABT-530 Wit NCT02243293 | AbbVie | Phase 2 / Phase 3 |
| Completed | An Efficacy and Safety Study of Grazoprevir (MK-5172) + Elbasvir (MK-8742) in the Treatment of Chronic Hepatit NCT02105688 | Merck Sharp & Dohme LLC | Phase 3 |
| Completed | Efficacy and Safety of Oral Regimens for the Treatment of Chronic HCV Infection NCT02202980 | Gilead Sciences | Phase 2 |
| Completed | A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Co-administration of ABT-493 and ABT-530 Wit NCT02243280 | AbbVie | Phase 2 |
| Completed | An Efficacy and Safety Study of Grazoprevir (MK-5172) + Elbasvir (MK-8742) in the Treatment of Chronic Hepatit NCT02105662 | Merck Sharp & Dohme LLC | Phase 3 |
| Completed | Effect of Camel Milk on Chronic Hepatitis C NCT02216045 | Mashhad University of Medical Sciences | Phase 2 |
| Completed | Study of Efficacy and Safety of Grazoprevir (MK-5172) + Elbasvir (MK-8742) in Chronic Hepatitis C Participants NCT02115321 | Merck Sharp & Dohme LLC | Phase 2 / Phase 3 |
| Withdrawn | Safety and Tolerability of Boceprevir in Combination With Peginterferon Alfa-2b Plus Ribavirin for the Treatme NCT01641666 | Merck Sharp & Dohme LLC | Phase 3 |
| Terminated | Liver Test Study of Using JKB-122 in Hepatitis C Virus (HCV)-Positive Patients Nonresponsive to Prior Interfer NCT02293941 | TaiwanJ Pharmaceuticals Co., Ltd | Phase 2 |
| Completed | Hepatocellular Carcinoma in HIV-infected Patients NCT02785835 | Hospital Universitario de Valme | — |
| Completed | A Study to Evaluate the Safety and Antiviral Effect of ABT-450/Ritonavir and ABT-530 Coadministered With and W NCT02068222 | AbbVie | Phase 2 |
| Withdrawn | Evaluation of the National Treatment Program of Hepatitis C in Egypt NCT02101177 | ANRS, Emerging Infectious Diseases | — |
| Withdrawn | Efficacy and Safety of the Combination Vitamin D With Standard of Care in Egyptian Patients With Untreated Chr NCT02099604 | ANRS, Emerging Infectious Diseases | Phase 3 |
| Completed | Evaluation of Safety, Tolerability, and Antiviral Activity of Chlorcyclizine HCl in Patients With Chronic Hepa NCT02118012 | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Phase 1 / Phase 2 |
| Terminated | Study Assessing Single and Multiple Doses of IDX21459 in Healthy and HCV-Infected Subjects NCT02112942 | Merck Sharp & Dohme LLC | Phase 1 |
| Completed | Effect of ASV and DCV Therapy on the Quality of Immune Status in Chronic HCV Patients NCT02282709 | Foundation for Liver Research | Phase 3 |
| Completed | The SIM-SOF Trial for Hepatitis C NCT02168361 | Center For Hepatitis C, Atlanta, GA | Phase 4 |
| Completed | A Study to Evaluate the Safety and Antiviral Effect of Multiple Doses of ABT-493 and ABT-530 in Adults With Ge NCT01995071 | AbbVie | Phase 2 |
| Completed | Single and Multiple Dose Study of Uprifosbuvir (MK-3682/IDX21437) in Healthy and Hepatitis C Virus (HCV)-Infec NCT01974687 | Merck Sharp & Dohme LLC | Phase 1 / Phase 2 |
| Unknown | Pilot Study of Ezetimibe for Chronic Hepatitis C Virus (HCV) Infection NCT02126137 | Pontificia Universidad Catolica de Chile | Phase 1 |
| Completed | The Pharmacokinetics of Grazoprevir (MK-5172) and Elbasvir (MK-8742) in Participants With Renal Insufficiency NCT01937975 | Merck Sharp & Dohme LLC | Phase 1 |
| Unknown | A Pilot Study of Boceprevir for the Treatment of Genotype 6 HCV NCT01949168 | St Vincent's Hospital Melbourne | Phase 2 |
| Completed | Association of Vitamin D Binding Protein Polymorphisms With Response to HCV Therapy NCT02788682 | Cairo University | — |
| Completed | A Multipart, Open-label Study to Evaluate the Safety and Efficacy of ABT-450/r/ABT-267 With and Without ABT-33 NCT01939197 | AbbVie | Phase 2 / Phase 3 |
| Completed | Long-Term Extension Study of Miravirsen Among Participants With Genotype 1 Chronic Hepatitis C (CHC) Who Have NCT02508090 | Hoffmann-La Roche | — |
| Completed | Interferon/Ribavirin-Free Sofosbuvir Based Treatment (AURIC) NCT02628717 | Medical University of Vienna | — |
| Completed | Efficacy and Safety Study of PEG-IFN-SA and Ribavirin to Treat Chronic Hepatitis C NCT01903278 | Beijing Kawin Technology Share-Holding Co., Ltd. | Phase 3 |
| Unknown | Trial Comparing the Efficacy, Tolerability and Safety Between Three Arms in Treatment of HCV in Egyptian Popul NCT01896609 | MinaPharm Pharmaceuticals | Phase 4 |
| Completed | A Phase 2 Study to Evaluate the Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of VX-135 and Daclata NCT01842451 | Vertex Pharmaceuticals Incorporated | Phase 2 |
| Completed | New Treatment Response in People With and Without Cirrhosis From Chronic Hepatitis C NCT01888900 | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Phase 2 |
| Completed | Study of PPI-668, BI 207127 and Faldaprevir, With and Without Ribavirin, in the Treatment of Chronic Hepatitis NCT01859962 | Presidio Pharmaceuticals, Inc. | Phase 2 |
| Completed | An Open-label, Single Arm, Phase 2 Study to Evaluate ABT-450/r/ABT-267 and ABT-333 With Ribavirin (RBV) in Adu NCT01911845 | AbbVie | Phase 2 |
| Completed | Efficacy and Safety of Sofosbuvir Containing Regimens for the Treatment of Chronic HCV Infection in Participan NCT01826981 | Gilead Sciences | Phase 2 |
| Completed | A Phase 1 Study to Evaluate the Pharmacokinetics of GS-5816 in Subjects With Normal Hepatic Function and Moder NCT01817985 | Gilead Sciences | Phase 1 |
| Completed | A Phase 2a, Dose-Ranging Study to Evaluate the Safety, Pharmacokinetics and Efficacy of VX-135 With Ribavirin NCT01790100 | Alios Biopharma Inc. | Phase 2 |
| Completed | Clinical Pharmacology Study of MP-424 NCT01766167 | Tanabe Pharma Corporation | Phase 1 |
| Completed | Birth-Cohort Evaluation to Advance Screening and Testing for Hepatitis C NCT02123212 | National Opinion Research Center | N/A |
| Withdrawn | Efficacy and Safety of Boceprevir in Combination With Peginterferon Alfa-2b Plus Ribavirin in Pediatric Subjec NCT01590225 | Merck Sharp & Dohme LLC | Phase 3 |
| Completed | A Phase 3, Open-label Study to Investigate the Efficacy and Safety of Sofosbuvir Plus Ribavirin in Chronic Gen NCT01783678 | Gilead Sciences | Phase 3 |
| Unknown | A Pilot Study to Treat Patients With Chronic Hepatitis C Virus (HCV) Genotype 1 and End-Stage Renal Disease (E NCT01731301 | Liver Institute of Virginia | Phase 4 |
| Completed | A Study to Evaluate the Safety and Effect of Treatment With Experimental Antiviral Drugs in Combination With P NCT01609933 | AbbVie (prior sponsor, Abbott) | Phase 2 |
| Completed | Viral Kinetics in HCV Clearance in Subjects With Hemophilia NCT01704521 | Kenneth Sherman | Phase 1 |
| Completed | A Phase 2 Study to Evaluate the Safety and Efficacy of VX-135 With Ribavirin in Treatment-Naïve Subjects With NCT01726946 | Vertex Pharmaceuticals Incorporated | Phase 2 |
| Completed | Evaluating Fine Needle Aspiration to Measure Hepatic Vaniprevir (MK-7009) Concentrations in Participants With NCT01678131 | Merck Sharp & Dohme LLC | Phase 1 |
| Completed | A Study to Evaluate the Safety, Tolerability, and Effectiveness of a 12-Week Combination Therapy of TMC647055 NCT01724086 | Janssen R&D Ireland | Phase 2 |
| Completed | A Phase Ⅱ Dose-escalating Study of PEG-IFN-SA and Ribavirin in IFN Naive Patients With Chronic Hepatitis C NCT01908335 | Beijing Kawin Technology Share-Holding Co., Ltd. | Phase 2 |
| Unknown | Hansenula-derived Pegylated Interferon in Treatment of Patients With Chronic Hepatitis C NCT01649245 | MinaPharm Pharmaceuticals | Phase 4 |
| Unknown | Effects of Metformin, Pegylated Interferon Alpha and Ribavirin for Chronic Hepatitis C With Insulin Resistance NCT01664845 | Kaohsiung Veterans General Hospital. | Phase 2 / Phase 3 |
| Terminated | Sustained Virological Response (SVR)Rate of Pegasys Plus Ribavirin in Patients With Chronic Hepatitis C NCT01639547 | Chang Gung Memorial Hospital | N/A |
| Completed | Histologic Changes and Noninvasive Assessment in Hepatitis C Patients Treated with Peginterferon Alpha-2a and NCT01634919 | Seoul National University Boramae Hospital | — |
| Completed | Sofosbuvir + Ribavirin for 12 or 16 Weeks in Treatment Experienced Subjects With Chronic Genotype 2 or 3 HCV I NCT01604850 | Gilead Sciences | Phase 3 |
| Completed | Sofosbuvir With Peginterferon Alfa 2a and Ribavirin for 12 Weeks in Treatment-Naive Subjects With Chronic Geno NCT01641640 | Gilead Sciences | Phase 3 |
| Completed | Drug Interaction Study to Assess the Effect of Co-Administered Miravirsen and Telaprevir in Healthy Subjects NCT01646489 | Santaris Pharma A/S | Phase 1 |
| Completed | Open-Label Study of Sofusbuvir+Ribavirin With or Without Peginterferon Alfa-2a in Subjects With Chronic HCV In NCT01625338 | Gilead Sciences | Phase 3 |
| Unknown | Vitamin D as an add-on Therapy With Pegylated Interferon and Ribavirin for Chronic Hepatitis c NCT01655966 | Cairo University | Phase 3 |
| Completed | Effect of Teleprevir in Triple Therapy on Intrahepatic Immunological Mechanisms NCT01641094 | Foundation for Liver Research | — |
| Withdrawn | 24 VS 48-WEEK TREATMENT WITH PEG-IFN ALPHA-2A IN PATIENTS WITH GENOTYPE 2/3 CHRONIC HEPATITIS C NCT01517308 | Federico II University | Phase 3 |
| Withdrawn | Evaluation of Hepatic Pharmacokinetics for Grazoprevir (MK-5172) in Participants With Chronic Hepatitis C (MK- NCT01547312 | Merck Sharp & Dohme LLC | Phase 1 |
| Completed | Efficacy and Safety of MP-424, Peginterferon Alfa-2b and Ribavirin in Relapser Genotype 2 Hepatitis C Infected NCT01466192 | Tanabe Pharma Corporation | Phase 3 |
| Completed | An Efficacy and Safety Study of Telaprevir in Patients Infected With Both Chronic Hepatitis C Virus (HCV-1) an NCT01513941 | Janssen-Cilag International NV | Phase 3 |
| Completed | Efficacy and Safety Study of Peginterferon Alfa-2b in Chinese Chronic Hepatitis C Patients NCT01581398 | Xiamen Amoytop Biotech Co., Ltd. | Phase 3 |
| Withdrawn | Multiple Ascending Dose Study of BMS-929075 in Hepatitis C Virus (HCV) Infected Patients NCT01525212 | Bristol-Myers Squibb | Phase 1 |
| Completed | Effect of Boceprevir on HCV-specific T Cell Responses NCT01403181 | Azienda Ospedaliero-Universitaria di Parma | — |
| Unknown | Pharmacogenomics Study on IL28B Genetic Variants in Chinese Children With Hepatitis C Virus Infection NCT01607021 | Beijing 302 Hospital | — |
| Terminated | Long Term Vitamin D Therapy in HCV Treated Patients NCT01997203 | Dr. Nadia AbdelAaty AbdelKader | Phase 3 |
| Terminated | HCV Treatment With Fluvastatin, Simvastatin to Improve Interferon Sensitivity NCT01377909 | Bader, Ted, M.D. | Phase 1 |
| Completed | Patient Self-management and Gene Guided Therapy for Chronic Hepatitis C NCT02006823 | Duke University | — |
| Completed | Sofosbuvir + Ribavirin for 12 Weeks in Subjects With Chronic Genotype 2 or 3 Hepatitis C Infection Who Are Int NCT01542788 | Gilead Sciences | Phase 3 |
| Completed | A Study to Assess the Relative Bioavailability Three New Formulations of Telaprevir in Healthy Subjects NCT01511432 | Vertex Pharmaceuticals Incorporated | Phase 1 |
| Unknown | BIP48 (Peginterferon Alfa 2b 48kDa) Compared With Pegasys® (Peginterferon 2a 40kDa) for Treatment of Chronic H NCT01623336 | The Immunobiological Technology Institute (Bio-Manguinhos) / Oswaldo Cruz Foundation (Fiocruz) | Phase 2 / Phase 3 |
| Completed | Keyhole Limpet Hemocyanin in Chronic Hepatitis C NCT01509391 | Medical University of Graz | N/A |
| Completed | Impact of Physician Directed Education on Patient Compliance With Hepatitis C Therapy NCT01405027 | Chronic Liver Disease Foundation | Phase 4 |
| Completed | Study to Determine the Effectiveness and Safety of a Three Drug Antiviral Combination Therapy to Treat Hepatit NCT01455090 | Bristol-Myers Squibb | Phase 2 |
| Completed | Response to Pegylated Interferon and Ribavirin in Chinese Patients With Chronic Hepatitis C Genotypes 1 Versus NCT01433887 | Third Affiliated Hospital, Sun Yat-Sen University | Phase 3 |
| Completed | Efficacy and Safety of MP-424, Peginterferon Alfa-2b and Ribavirin in Non-responder Genotype 2 Hepatitis C Inf NCT01468584 | Tanabe Pharma Corporation | Phase 3 |
| Unknown | Boceprevir/PegIFN α-2b/Riba in HCV+ Gt1 Menopausal Women, Nonresponders to PegIFN/Riba or Treatment-naives (ME NCT01457937 | University of Modena and Reggio Emilia | Phase 3 |
| Unknown | Oral Administration of Anti-CD3 Monoclonal Antibody in Non-responder Genotype-I Chronic Hepatitis C Subjects NCT01459419 | Inspira Medical AB | Phase 2 |
| Completed | ABT-450 With Ritonavir and ABT-267 and/or ABT-333 With and Without Ribavirin in Genotype 1 Hepatitis C Virus I NCT01464827 | AbbVie (prior sponsor, Abbott) | Phase 2 |
| Completed | Add Vitamin D With Standard of Care for Chronic Hepatitis C Patients NCT01439776 | Hanyang University | Phase 4 |
| Unknown | Does 3 Months Therapy With Vitamin D + Peg + Ribavirin Improve Sustained Virologic Response (SVR) in Genotype NCT01151397 | Ziv Hospital | N/A |
| Completed | The Effect of High Dose Vitamin C on the Liver Function in Chronic Hepatitis Patients NCT01413360 | Seoul National University Hospital | Phase 4 |
| Terminated | GS-5885, GS-9451 With Peginterferon Alfa 2a (PEG) and Ribavirin in Treatment-Naïve Subjects With Chronic Genot NCT01384383 | Gilead Sciences | Phase 2 |
| Completed | Q-Trial in Patients With Hepatitis C NCT01438320 | University of California, Los Angeles | Phase 1 |
| Completed | Menopause is a Critical Factor in Determining Failure of Antiviral Therapy in Women With Chronic Hepatitis C NCT01402583 | Prof. Facchinetti Fabio | — |
| Completed | Pharmacogenomic Research in Korean Patients With Hepatitis C NCT01453244 | Inje University | — |
| Completed | Study to Determine the Safety and Effectiveness of Antiviral Combination Therapy to Treat Hepatitis C Virus (H NCT01359644 | Bristol-Myers Squibb | Phase 2 |
| Unknown | A Randomized Trial of 24-Week Versus 48-Week Courses of Peginterferon Plus Ribavirin for Patients With Genotyp NCT01441804 | Third Affiliated Hospital, Sun Yat-Sen University | Phase 3 |
| Unknown | CHRONVAC-C Study Followed by Standard of Care in Chronic Hepatitis C Virus (HCV) Subjects NCT01335711 | ChronTech Pharma AB | Phase 2 |
| Completed | Study of ABT-267 in Treatment Naive Hepatitis C Virus (HCV) Genotype 1 Infected Subjects NCT01314261 | AbbVie (prior sponsor, Abbott) | Phase 2 |
| Completed | Study of the Efficacy and Safety of Pegnano Plus Barivir (Ribavirin) in Treatment-naïve Patients With Chronic NCT06922643 | Nanogen Pharmaceutical Biotechnology Joint Stock Company | Phase 4 |
| Completed | Drug Interaction Study Of Filibuvir With Methadone Among Subjects On Chronic Methadone Maintenance NCT01210404 | Pfizer | Phase 1 |
| Completed | Ribavirin Dose Optimization for the Treatment of Hepatitis C NCT01289496 | Centre hospitalier de l'Université de Montréal (CHUM) | Phase 2 |
| Completed | Predictive Factors of the Treatment Failure in Hepatitis C Virus (HCV) Infected Patients Treated With Telaprev NCT01577069 | Association HGE CHU Bordeaux Sud | — |
| Completed | French Cohort of Therapeutic Failure and Resistances in Patients Treated With a Protease Inhibitor (Telaprevir NCT01514890 | ANRS, Emerging Infectious Diseases | — |
| Unknown | Clinical Trial to Assess Safety and Efficacy of Combination Therapy: Hydroxychloroquine, Pegylated Interferon NCT01272310 | Sheba Medical Center | Phase 1 / Phase 2 |
| Completed | Efficacy of Nitazoxanide in the Treatment of Chronic Hepatitis C Virus (HCV) NCT01276756 | Cairo University | Phase 2 / Phase 3 |
| Completed | A Randomized Trial of 24-Week Versus 48-Week Courses of Peginterferon Plus Ribavirin for HCV Genotype-6 Patien NCT01263860 | Third Affiliated Hospital, Sun Yat-Sen University | Phase 3 |
| Completed | Efficacy of Vitamin D on Top of Pegylated Interferon and Ribavirin in Patients With Chronic Viral Hepatitis C NCT01226446 | French National Agency for Research on AIDS and Viral Hepatitis | Phase 2 |
| Unknown | Assessment of Liver FIBROsis by Real-time Tissue ELASTography in Chronic Liver Disease NCT01360879 | Kindai University | — |
| Unknown | Prediction of Incidence of Liver Cancer by Use of Real-time Tissue Elastography NCT01360892 | Kindai University | — |
| Completed | Extension Study SCI-SCV-HCV-P2-001: Long-Term FU in Subj Who Opt for Retreatment With Peg-INF and RBV After Co NCT01310205 | SciClone Pharmaceuticals | — |
| Completed | Efficacy and Safety of Ypeginterferon Alfa-2b in Chronic Hepatitis C NCT01140997 | Xiamen Amoytop Biotech Co., Ltd. | Phase 2 |
| Completed | A Drug-Drug Interaction Study Evaluating the Combination of IDX320 and IDX184 in Healthy Participants (MK-6844 NCT01157104 | Merck Sharp & Dohme LLC | Phase 1 |
| Completed | Study of VX-985 in Subjects With Chronic Hepatitis C NCT01144936 | Vertex Pharmaceuticals Incorporated | Phase 1 |
| Unknown | Study Comparing the Tolerability and Viral Reduction of the Combination of IFN a-2b XL + Ribavirin Versus Peg NCT01010646 | ANRS, Emerging Infectious Diseases | Phase 2 |
| Terminated | EXtended Therapy in Hepatitis C Genotype 3 Infected Patients NCT01095445 | University Health Network, Toronto | Phase 3 |
| Terminated | Role of FXR in Hepatitis C Virus Replication NCT01492998 | Hospices Civils de Lyon | N/A |
| Completed | Impact of Antiviral Therapy on Gastroesophageal Varices. NCT02758509 | Parc de Salut Mar | — |
| Unknown | PegIFN Alfa-2a and RBV for 16 or 24 Weeks in Patients With Chronic Hepatitis C(CHC) 2 With Rapid Virologic Res NCT01056172 | Pusan National University Yangsan Hospital | Phase 4 |
| Terminated | Pioglitazone vs. Placebo in Association With Pegylated Interferon and Ribavirin in HCV Patients With Insulin R NCT00927290 | French National Agency for Research on AIDS and Viral Hepatitis | Phase 3 |
| Completed | Study to Determine the Effectiveness of Antiviral Combination Therapy to Treat Hepatitis C Virus (HCV) Infecte NCT01012895 | Bristol-Myers Squibb | Phase 2 |
| Unknown | The Effects of Oral Hypoglycemic Agents on Chronic Hepatitis C Patients Receiving Peg-Intron Plus Ribavirin NCT01025765 | National Taiwan University Hospital | Phase 4 |
| Completed | Safety, Metabolism, and Antioxidant Activity of Silymarin and Green Tea Extract in Patients With Chronic Hepat NCT01018615 | University of North Carolina, Chapel Hill | Phase 1 |
| Completed | Study to Assess the Effect of BMS-790052 on the Pharmacokinetics of Ortho Tri-Cyclen® in Healthy Female Subjec NCT00983957 | Bristol-Myers Squibb | Phase 1 |
| Completed | Multiple Dose Study In Treatment Naive Subjects Infected With Hepatitis C Virus NCT00971308 | Bristol-Myers Squibb | Phase 1 |
| Withdrawn | Vitamin D Deficiency in Subjects With Chronic Hepatitis C Compared to Healthy Volunteers NCT01274013 | Avera McKennan Hospital & University Health Center | — |
| Terminated | Safety and Tolerability Study of the Monoclonal Antibody CT-011 in Patients With Chronic Hepatitis C Genotype NCT00962936 | CureTech Ltd | Phase 1 / Phase 2 |
| Completed | Proof-of-concept Study to Evaluate the Safety and Immunomodulatory Effects of SCV 07 as Monotherapy or in Comb NCT00968357 | SciClone Pharmaceuticals | Phase 2 |
| Completed | A Phase 1/2 Study of CF102 in Patients With Chronic Hepatitis C Genotype 1 NCT00790673 | Can-Fite BioPharma | Phase 1 / Phase 2 |
| Terminated | Pilot Study of Betaine + Combination Antiviral Therapy for Chronic Hepatitis C Genotype 1 Non-responder/Relaps NCT00882193 | University of Nebraska | EARLY_Phase 1 |
| Completed | Prospective Anti-Hepatitis C Virus (Anti-HCV) Trial of Peg-Interferon and Ribavirin in Subjects of First Natio NCT00957866 | University of Manitoba | Phase 4 |
| Withdrawn | Effects of Genotypes on Interferon Signaling in Chronic Hepatitis C NCT00876174 | University of Nebraska | — |
| Completed | Evaluation of RNA From the Liver Tissue Obtained in Patients With Chronic Hepatitis C (0000-123) NCT00828269 | Merck Sharp & Dohme LLC | Phase 1 |
| Completed | Peginterferon Alfa-2a Plus Ribavirin Combination Treatment in Chronic Hepatitis C Post-Renal Transplant Patien NCT00881582 | King Abdulaziz Medical City | Phase 4 |
| Completed | A Study of Debio 025 (Alisporivir) Combined With Peg-IFNα2a and Ribavirin in Treatment naïve Chronic Hepatitis NCT00854802 | Debiopharm International SA | N/A |
| Terminated | Impact of Hepatitis C Virus Variability on Steatosis NCT00843076 | University Hospital, Tours | — |
| Terminated | Efficacy of Long-term Ribavirin in Non-responders With Chronic Hepatitis C and Advanced Fibrosis NCT00840489 | Hospital Universitario Ramon y Cajal | Phase 2 |
| Completed | A Multiple Ascending Dose Study of BMS-650032 in HCV Infected Subjects NCT00722358 | Bristol-Myers Squibb | Phase 2 |
| Completed | Fourteen Day Safety of Low-Dose Tamoxifen in Patients With Chronic Hepatitis C Who Have Failed Standard Medica NCT00749138 | Bader, Ted, M.D. | Phase 1 |
| Completed | Efficacy and Safety of MP-424, Peginterferon Alfa-2b, and Ribavirin in Patients With Chronic Hepatitis C Who R NCT00780910 | Tanabe Pharma Corporation | Phase 3 |
| Completed | Study of the Effects of Motivational Enhancement Therapy on Alcohol Use in Chronic Hepatitis C Patients NCT00596960 | US Department of Veterans Affairs | N/A |
| Completed | High Dose Versus Standard Dose of Ribavirin in Patients With Chronic Hepatitis C, Genotype 3 NCT00830609 | Dr. Conrado Fernandez | Phase 4 |
| Terminated | Study of Safety and Tolerability of Multiple Intravenous Doses of ANZ-521 in Adults With Chronic Hepatitis C V NCT00800007 | Anza Therapeutics, Inc. | Phase 1 / Phase 2 |
| Completed | Safety, Tolerability, and Antiviral Activity of ANA598 in Patients With Genotype-1 Chronic HCV Infection NCT00782353 | Hoffmann-La Roche | Phase 1 |
| Completed | Safety and Efficacy of Albumin Interferon Administered Every 4 Weeks in Genotype 2/3 Hepatitis C Patients NCT00759200 | Novartis | Phase 2 |
| Completed | Safety Study of SD-101 (a Novel C Type Toll-like Receptor 9 (TLR9) Agonist) for the Treatment of Chronic Hepat NCT00823862 | Dynavax Technologies Corporation | Phase 1 |
| Completed | Antioxidant and Immunomodulator Properties of Viusid in Patients With Chronic Hepatitis C NCT00778843 | Catalysis SL | Phase 3 |
| Completed | High-Dose Ribavirin and Peginterferon to Treat Chronic Hepatitis C Genotype 1 NCT00735969 | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Phase 2 |
| Completed | Albinterferon Alfa 2b Single Dose in Japanese Chronic Hepatitis C Patients NCT00724776 | Novartis | Phase 1 |
| Unknown | HDV-Interferon in the Treatment of Chronic Hepatitis C Nonresponders and Naive Hepatitis C Patients NCT00703872 | Hepasome Pharmaceuticals | Phase 2 |
| Completed | A Multiple Ascending Dose Study of Daclatasvir (BMS-790052) in Hepatitis C Virus Genotype 1 Infected Subjects NCT00663208 | Bristol-Myers Squibb | Phase 2 |
| Completed | A Single Ascending Dose Study of BMS-791325 in HCV Infected Subjects NCT00664625 | Bristol-Myers Squibb | Phase 1 / Phase 2 |
| Completed | Hepatitis C Treatment and Atherosclerosis NCT00659256 | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | — |
| Withdrawn | Pilot Comparison of Standard Antiviral Therapy With and Without 12 Weeks of Betaine in Genotype 1 Naive Patien NCT00571714 | University of Nebraska | N/A |
| Completed | Phase II Trial of Silymarin for Patients With Chronic Hepatitis C Who Have Failed Conventional Antiviral Treat NCT00680342 | National Center for Complementary and Integrative Health (NCCIH) | Phase 2 |
| Terminated | High-dose Ribavirin in Treatment of Chronic Hepatitis C Genotype 1 or 4 NCT00662220 | Foundation for Liver Research | Phase 3 |
| Completed | Study of Nitazoxanide, Peginterferon Alfa-2a and Ribavirin in Treatment-Naive Hepatitis C Patients NCT00637923 | Romark Laboratories L.C. | Phase 2 |
| Completed | A Single Ascending Dose Study of BMS-650032 in HCV Infected Subjects NCT00559247 | Bristol-Myers Squibb | Phase 1 / Phase 2 |
| Completed | Observational Study Evaluating the Quality of Pegylated Interferon Alfa-2a and Ribavirin Treatment for Chronic NCT02106156 | Hoffmann-La Roche | — |
| Completed | Safety and PK Study of MP-424 to Treat Chronic Hepatitis C NCT00591214 | Tanabe Pharma Corporation | Phase 1 |
| Completed | A Single Ascending Dose Study of Daclatasvir (BMS-790052) in Hepatitis C Virus Infected Subjects NCT00546715 | Bristol-Myers Squibb | Phase 1 / Phase 2 |
| Completed | Peginterferon Alfa-2a and Ribavirin for Genotype 2 Chronic Hepatitis C: Duration and Ribavirin Dose Stratified NCT00532701 | National Taiwan University Hospital | Phase 4 |
| Completed | High Dose Ribavirin in the Treatment of Chronic Hepatitis C NCT00944684 | University of Bern | Phase 2 |
| Completed | An Open-Label Study of Telaprevir Administered Every 12 or 8 Hours in Combination With One of Two Pegylated In NCT00528528 | Tibotec BVBA | Phase 2 |
| Unknown | Exploration of Chronic Hepatitis C Infection Receiving 24-week Interferon-α With Ribavirin Treatments NCT01178749 | National Taiwan University Hospital | — |
| Unknown | Pegylated-Interferon and Ribavirin in Hepatitis C Patients With Persistently Normal Alanine Aminotransferase L NCT00575627 | University of Turin, Italy | Phase 4 |
| Completed | A Study of Debio 025 in Combination With PegIFN Alpha-2a and Ribavirin in Chronic HCV Patients Non-responders NCT00537407 | Debiopharm International SA | Phase 2 |
| Completed | Phase 1b Study of Omega DUROS® in Patients With Chronic Hepatitis C Who Relapsed After Prior Treatment NCT00519792 | Intarcia Therapeutics | Phase 1 |
| Terminated | A Study of the PK, Safety and Antiviral Activity of A-831 in HCV Carriers NCT00522808 | Arrow Therapeutics | Phase 1 / Phase 2 |
| Completed | The Effects of Adding TCM-700C on the Standard Combination Treatment for Patients With Genotype 1 Hepatitis C NCT00556504 | TCM Biotech International Corp. | Phase 2 |
| Completed | Study of Nitazoxanide, Peginterferon Alfa-2a and Ribavirin for the Treatment of Hepatitis C NCT00495391 | Romark Laboratories L.C. | Phase 2 |
| Completed | Subcutaneous Continuous Infusion of Interferon Alfa-2b and Ribavirin in Hepatitis C Genotype 1 Nonresponders NCT00624325 | Foundation for Liver Research | Phase 2 / Phase 3 |
| Completed | Fluvastatin, Rosuvastatin Added to Pegylated Interferon and Ribavirin NCT00487318 | Bader, Ted, M.D. | Phase 2 |
| Unknown | Phase IV Study to Evaluate the Efficacy/Safety to Extend Treatment and High Dose of Ribavirin in co-Infected P NCT00526448 | Hospital Carlos III, Madrid | Phase 4 |
| Completed | Pegylated Interferon Alfa-2a Plus Low Dose Ribavirin for Treatment-Naïve Hemodialysis Patients With Chronic He NCT00491244 | National Taiwan University Hospital | Phase 4 |
| Completed | S-Adenosyl Methionine (SAMe) to Treat Patients With Chronic Hepatitis C NCT00475176 | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Phase 2 |
| Completed | Prediction of Significant Hepatic Fibrosis in HCV Carriers With PNALT by SAPI- A Validation Study NCT00466271 | National Taiwan University Hospital | — |
| Completed | Safety, PK and Efficacy of 15 Days of SCY-635 Treatment in Hepatitis C Patients NCT01290965 | Scynexis, Inc. | Phase 1 |
| Terminated | Evaluating Safety and Efficacy In Hepatitis C Patients After PegIntron Pen Treatment (Study P04896) NCT01340573 | Merck Sharp & Dohme LLC | — |
| Completed | Taribavirin Phase 2 Dose Finding Study for the Treatment of Hepatitis C Virus (HCV) NCT00446134 | Bausch Health Americas, Inc. | Phase 2 |
| Completed | Trial of MitoQ for Raised Liver Enzymes Due to Hepatitis C NCT00433108 | Antipodean Pharmaceuticals, Inc. | Phase 2 |
| Completed | Efficacy of Albumin Interferon Alfa-2b With Ribavirin Compared to Peg-IFN Alfa-2a With Ribavirin in IFN Naive NCT00411385 | Human Genome Sciences Inc. | Phase 3 |
| Completed | HCV Genotype 1a Shows a Better Virological Response to Antiviral Therapy Than HCV Genotype 1b NCT01342003 | Azienda Ospedaliera San Camillo Forlanini | — |
| Completed | Pegylated Interferon Plus Ribavirin in Treating Older Patients With Chronic Hepatitis C NCT00629824 | Kaohsiung Medical University Chung-Ho Memorial Hospital | Phase 4 |
| Terminated | Combination Therapy With Pegylated Interferon and Ribavirin in Patients With Chronic Hepatitis C Genotype 2 or NCT00641654 | Göteborg University | Phase 4 |
| Unknown | Peginterferon Plus Ribavirin for Hepatitis C Patients Concomitant With Hepatocellular Carcinoma NCT00834860 | Kaohsiung Medical University Chung-Ho Memorial Hospital | Phase 4 |
| Completed | Retreatment of Chronic Hepatitis C Non-responders With Pegylated Interferon Alpha Plus Ribavirin Plus Pioglita NCT00433069 | University Hospital, Geneva | Phase 2 |
| Completed | Safety and Efficacy of SCH 503034 in Previously Untreated Subjects With Chronic Hepatitis C Infected With Geno NCT00423670 | Merck Sharp & Dohme LLC | Phase 2 |
| Completed | Phase I Hepatitis C Vaccine Trial of Virosome-formulated Peptides NCT00445419 | Pevion Biotech Ltd | Phase 1 |
| Completed | Efficacy of Albumin Interferon Alfa-2b With Ribavirin Compared With Peg-IFN Alfa-2a With Ribavirin in IFN Naiv NCT00402428 | Human Genome Sciences Inc. | Phase 3 |
| Unknown | Prevention of Depression With Omega-3 Fatty Acids in Chronic Carriers of Hepatitis C Treated With Interferon A NCT00408304 | Bnai Zion Medical Center | Phase 2 |
| Unknown | Observational Study of B-Cell Non Hodgkin Lymphomas (NHL) Associated With Hepatitis C Virus (HCV) NCT01545544 | ANRS, Emerging Infectious Diseases | — |
| Completed | Four Arms, Multicenter Study of Tailored Regimens With Peginterferon Plus Ribavirin for Genotype 2 Chronic Hep NCT00540345 | Kaohsiung Medical University Chung-Ho Memorial Hospital | Phase 4 |
| Completed | Study to Evaluate Drug-drug Interaction Between Valopicitabine and Ribavirin NCT00395421 | Merck Sharp & Dohme LLC | Phase 2 |
| Unknown | Pegylated-Interferon and Ribavirin Plus Metformin in the Treatment of Chronic HCV Infection and Insulin Resist NCT00370617 | University of Turin, Italy | Phase 4 |
| Completed | Study to Evaluate the Treatment for Chronic Hepatitis C With Normal Transaminases in HIV Positive Patients NCT01684787 | Miguel Santin | Phase 4 |